OXB Insider Trading

Insider Ownership Percentage: 16.19%
Insider Buying (Last 12 Months): £149,947.40
Insider Selling (Last 12 Months): GBX 0

Oxford Biomedica Insider Trading History Chart

This chart shows the insider buying and selling history at Oxford Biomedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oxford Biomedica Share Price & Price History

Current Price: GBX 202.50
Price Change: Price Decrease of -7 (-3.34%)
As of 04/12/2024 01:00 AM ET

This chart shows the closing price history over time for OXB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Oxford Biomedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2023Michael HaydenInsiderBuy10,000GBX 193£19,300
9/26/2023Dame Kay DaviesInsiderBuy1,000GBX 291£2,910
9/20/2023Roch DoliveuxInsiderBuy36,130GBX 274£98,996.20
7/3/2023Catherine MoukheibirInsiderBuy6,684GBX 430£28,741.20
10/11/2022Catherine MoukheibirInsiderBuy8,910GBX 317£28,244.70
4/29/2022Catherine MoukheibirInsiderBuy2,467GBX 571£14,086.57
4/20/2022Stuart PaynterInsiderBuy3,915GBX 508£19,888.20
9/29/2021Michael HaydenInsiderBuy1,910GBX 1,507£28,783.70
6/23/2021Siyamak RastyInsiderBuy2,235GBX 1,288£28,786.80
See Full Table

SEC Filings (Institutional Ownership Changes) for Oxford Biomedica (LON:OXB)

58.10% of Oxford Biomedica stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Oxford Biomedica logo
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Read More on Oxford Biomedica

Today's Range

Now: GBX 202.50
Low: 198
High: 209.67

50 Day Range

MA: GBX 188.26
Low: 167.20
High: 215

52 Week Range

Now: GBX 202.50
Low: 164.29
High: 474.50

Volume

194,395 shs

Average Volume

228,489 shs

Market Capitalization

£202.42 million

P/E Ratio

N/A

Dividend Yield

4.57%

Beta

1

Who are the company insiders with the largest holdings of Oxford Biomedica?

Oxford Biomedica's top insider investors include:
  1. Catherine Moukheibir (Insider)
  2. Dame Kay Davies (Insider)
  3. Michael Hayden (Insider)
  4. Roch Doliveux (Insider)
  5. Stuart Paynter (Insider)
Learn More about top insider investors at Oxford Biomedica.